SML0596

雷尼酸锶

≥98% (HPLC)

• 别名: 2-[N,N-Di(carboxymethyl)amino]-3-cyano-4-carboxymethylthiophene-5-carboxylic acid strontium salt, 5-[Bis(carboxymethyl)amino]-2-carboxy-4-cyano-3-thiopheneacetic acid, strontium salt, Distrontium renelate, Ranelic acid strontium salt
• 经验公式（希尔记法）: C₁₂H₆N₂O₈SSr₂
• CAS号: 135459-87-9
• 分子量: 513.49
• 分類程式碼代碼: 12352200
• NACRES: NA.77

属性

• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: H₂O: 1 mg/mL, clear (warmed)
• 儲存溫度: −20°C
• InChI: 1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4
• InChI 密鑰: XXUZFRDUEGQHOV-UHFFFAOYSA-J

说明

生化／生理作用

Strontium ranelate is a dual action bone agent (DABA). It inhibits bone resorption and stimulates bone formation, inhibiting osteoclast differentiation while activating gene expression in osteoblasts. While its exact mechanism of action is unknown, one hypothesis is that both anabolic and anti-catabolic activities may involve antagonizing nuclear factor-KB (NF-KB) activation in bone cells. Strontium ranelate has been shown to inhibit the receptor activator of NF-KB ligand (RANKL)-induced nuclear translocation of NF-KB and activator protein-1. Strontium ranelate has been used clinically for the treatment of osteoporosis and a recent multinational study indicates the drug can also be used to treat osteoarthritis.

特點和優勢

This compound is featured on the Cytokine Receptors (Tumor Necrosis Receptor Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

安全信息

• 象形圖: GHS07
• 訊號詞: Warning
• 危險聲明: H302 + H312 + H332
• 防範說明: P261 - P264 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312
• 危險分類: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable